Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study
Gut and Liver · 15.07.2024 · 18 (4) · 729-736
DOI: 10.5009/gnl230164 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Gut and Liver, online erschienen am 22.12.2023. Verfasst von Dong Kee Jang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of…. Hauptthemen laut MEDLINE: Ampulla of Vater, Palliative Care, Adenocarcinoma, Common Bile Duct Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korean Society of Gastrointestinal Cancer Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Aims: : Palliative chemotherapy (PC) is not standardized for patients with advanced ampulla of Vater adenocarcinoma (AA). This multicenter, retrospective study evaluated first-line PC outcomes in patients with AA. Methods: : Patients diagnosed with AA between January 2010 and December 2020 who underwent PC were enrolled from 10 institutions. Overall survival (OS) and progression-free survival (PFS) according to the chemotherapy regimen were analyzed. Results: : Of 255 patients (mean age, 64.0±10.0 years; male, 57.6%), 14 (5.5%) had locally advanced AA and 241 (94.5%) had metastatic AA. Gemcitabine plus cisplatin (GP) was administered as first-line chemotherapy to 192 patients (75.3%), whereas capecitabine plus oxaliplatin (CAPOX) was administered to 39 patients (15.3%). The median OS of all patients was 19.8 months (95% confidence interval [CI], 17.3 to 22.3), and that of patients who received GP and CAPOX was 20.4 months (95% CI, 17.2 to 23.6) and 16.0 months (95% CI, 11.2 to 20.7), respectively. The median PFS of GP and CAPOX patients were 8.4 months (95% CI, 7.1 to 9.7) and 5.1 months (95% CI, 2.5 to 7.8), respectively. PC for AA demonstrated improved median outcomes in both OS and PFS compared to conventional bile duct cancers that included AA. Conclusions: : While previous studies have shown mixed prognostic outcomes when AA was analyzed together with other biliary tract cancers, our study unveils a distinct clinical prognosis specific to AA on a large scale with systemic anticancer therapy. These findings suggest that AA is a distinct type of tumor, different from other biliary tract cancers, and AA itself could be expected to have a favorable response to PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
- Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
- Division of Gastroenterology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
ORCID-Profile: Dong Kee Jang, So Jeong Kim, Hwe Hoon Chung, Jae Min Lee, Seung Bae Yoon, Jong-Chan Lee, Dong Woo Shin, Jin-Hyeok Hwang, Min Kyu Jung, Yoon Suk Lee, Hee Seung Lee, Joo Kyung Park
Förderung
- Korean Society of Gastrointestinal Cancer Research
Zitieren
APA
Jang, D. K., Kim, S. J., Chung, H. H., Lee, J. M., Yoon, S. B., Lee, J. C., Shin, D. W., Hwang, J. H., Jung, M. K., Lee, Y. S., Lee, H. S., Park, J. K., & Korean Society of Gastrointestinal Cancer (2024). Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study. Gut and Liver, 18(4), 729-736. https://doi.org/10.5009/gnl230164
Vancouver
Jang DK, Kim SJ, Chung HH, Lee JM, Yoon SB, Lee JC, et al. Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study. Gut and Liver. 2024;18(4):729-736. doi:10.5009/gnl230164
BibTeX
@article{Jang2024,
author = {Jang, Dong Kee and Kim, So Jeong and Chung, Hwe Hoon and Lee, Jae Min and Yoon, Seung Bae and Lee, Jong-Chan and Shin, Dong Woo and Hwang, Jin-Hyeok and Jung, Min Kyu and Lee, Yoon Suk and Lee, Hee Seung and Park, Joo Kyung and Korean Society of Gastrointestinal Cancer, Korean Society of Gastrointestinal Cancer},
title = {Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study},
journal = {Gut and Liver},
year = {2024},
volume = {18},
number = {4},
pages = {729--736},
doi = {10.5009/gnl230164}
}
EUVIMED